Prenumeration
Eevia Health Plc (”Eevia” or the “Company”) announced on Friday, January 12th, that the Company has entered into negotiations with a European food manufacturer, with annual revenue amounting to approx. EUR 500m, to manufacture a new plant extract (the “Product”) with the potential to significantly contribute to Eevia’s topline and profits in 2025. The manufacturing would start earliest in December 2024 and will require 20% to 40% of Eevia's annual production capacity for 2025, with an option to extend both annual volumes and the contract period till 2027. The parties expect to finalize negotiations by the end of Q1-24.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity analysis houses with a focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of comments on Eevia Health. Readers may assume that Analyst Group has received compensation for making the commentary. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.